Dr. Reddy's Board Approves Audited FY26 Results, Recommends Final Dividend of ₹8 Per Share
Dr. Reddy's Laboratories announced its audited financial results for FY26. The company recommended a final dividend of ₹8 per share. The 42nd AGM will be held on July 23, 2026. Key appointments and re-appointments were also approved.
The recommendation of a final dividend and key board appointments are significant corporate actions. The financial results, despite some one-off impacts, provide a comprehensive update on the company's performance.
The company announced positive corporate actions like dividend recommendation and board appointments, alongside financial results. Although there were one-off impacts on the financials, the overall outlook and corporate governance actions are viewed positively.
Dr. Reddy's Laboratories Limited announced the outcome of its Board Meeting held on May 12, 2026. The Board approved the audited financial results for the quarter and financial year ended March 31, 2026, presenting both IFRS and Ind AS consolidated and standalone financial statements.
Key decisions included the recommendation of a final dividend of ₹8 per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The record date for this dividend has been set as July 10, 2026.
The Board also approved the convening of the 42nd AGM on Thursday, July 23, 2026. Several re-appointments and appointments were also approved, including the re-appointment of Dr. K P Krishnan as an Independent Director for a second term, the appointment of Mr. Srikanth Velamakanni as an Additional Director (Independent), and the appointment of M/s Deloitte Haskins & Sells, LLP as Statutory Auditors for a five-year term. M/s Sagar & Associates were re-appointed as Cost Auditors for FY2026-27. Additionally, Mr. Sandeep Khandelwal was elevated to Senior Management Personnel, effective May 12, 2026.
The financial results for the quarter ended March 31, 2026, showed revenues of ₹75,162 million and a profit after tax attributable to equity holders of ₹2,201 million. For the full financial year ended March 31, 2026, revenues were ₹335,933 million and profit after tax was ₹42,850 million. The company's press release highlighted several one-off impacts on the results, including a Shelf Stock Adjustment for lenalidomide, impairments related to CAR-T assets and Eftilagimod Alfa, and provisions for VAT liability.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.